The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...
Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...
The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...